1 **Full title: EBV deletions as biomarkers of response to treatment of Chronic Active Epstein Barr**

2 **Virus**

3 Authors: Cristina Venturini¹, Charlotte J Houldcroft², Arina Lazareva³, Fanny Wegner¹, Sofia
4 Morfopoulou¹, Persis J. Amrolia³, Zainab Golwala⁴, Anupama Rao⁴, Stephen D. Marks^{5,6}, Jacob
5 Simmonds⁴, Tetsushi Yoshikawa⁷, Paul J. Farrell⁸, Jeffrey I. Cohen⁹, Austen J. Worth¹⁰, Judith
6 Breuer^{1,4}

7 Affiliations:

8 ¹ Institute of Child Health, University College London, London, UK

9 ² Department of Medicine, University of Cambridge, Cambridge, UK

10 ³ Bone Marrow Transplantation Department, Great Ormond Street Hospital for Children NHS
11 Foundation Trust, London, UK

12 ⁴ Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

13 ⁵ Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS
14 Foundation Trust, London, UK

15 ⁶ University College London Great Ormond Street Institute of Child Health, NIHR Great Ormond
16 Street Hospital Biomedical Research Centre, London, UK

17 ⁷ Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.

18 ⁸ Section of Virology, Department of Infectious Disease, Imperial College Faculty of Medicine,
19 London, UK

20 ⁹ Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases,
21 Bethesda, Maryland, USA

22 ¹⁰ Department of Immunology, Great Ormond Street Hospital for Children NHS Foundation
23 Trust, London, UK

24

25 Corresponding author: Judith Breuer, Division of Institute Child Health, University College London,

26 30 Guilford St, Holborn, London WC1N 1EH. Contact email: j.breuer@ucl.ac.uk.

27

28 Abbreviations:

29 EBV, Epstein-Barr Virus; CAEBV, Chronic active Epstein Barr Virus; PBSCT, peripheral blood stem cell

30 transplant; HLH, Hemophagocytic Lymphohistiocytosis; IM, Infectious Mononucleosis; PTLD, Post

31 Transfusion Lymphoproliferative Disease; HL, Hodgkin's lymphoma; PID, Primary Immunodeficiency.

32

Abstract:

Chronic active Epstein Barr Virus (CAEBV) is a rare condition occurring in previously healthy individuals associated with persistent EBV viraemia, fever, lymphadenopathy and hepatosplenomegaly. Viral deletions have been found in CAEBV and other lymphomas. However, it is unclear how stable these deletions are, whether they are present in different sites and how they evolve overtime. We sequenced fourteen longitudinal blood samples from three European CAEBV patients and compared with CAEBV saliva samples and other sequences from EBV-related conditions. We observed large EBV deletions in blood, but not saliva from CAEBV patients. Deletions were stable over time but were lost following successful treatment. Our results are consistent with the likelihood that certain deletions in the virus from CAEBV patients are associated with the evolution and persistence of haematological clones. We propose that the loss of deletions following successful treatment should be investigated as a potential biomarker to aid CAEBV management.

48 Introduction

49 Epstein-Barr virus (EBV) infects >95% of the population worldwide (Longnecker et al., 2013). A small
50 number of patients develop life-threatening persistence of high level/sustained EBV replication
51 following an infectious mononucleosis syndrome, often associated with splenomegaly and hepatitis
52 (Cohen et al., 2011). Chronic active EBV (CAEBV) (see “Clinical definitions” in Supplementary
53 materials) is characterised by infiltration of tissues by EBV positive T, NK or less frequently B cells
54 and can progress into lymphoproliferative disease. Clonal expansion of EBV-infected T or NK cells
55 containing identical EBV genome and chromosomal abnormalities is well described with both some
56 oligo and polyclonal populations of EBV genomes found (Kimura, 2006; Ohshima et al., 1997;
57 Quintanilla-Martinez et al., 2000).

58

59 To date, CAEBV has been mostly described in Asian or South/Central American patients (Kimura &
60 Cohen, 2017). Frequent deletions in the EBV genome have been found in samples from Japanese
61 CAEBV patients (35%) and other EBV-driven neoplasms (Murata et al., 2020; Okuno et al., 2019;
62 Peng et al., 2019). However, it is unclear if these deletions are specific for Asian EBV strains,
63 whether they are present in viral genomes in different sites and how they evolve overtime.

64

65 We sequenced EBV from serial blood samples obtained from three UK patients with CAEBV. The
66 results were compared with sequences from saliva of CAEBV patients and blood and tissue from
67 other benign and malignant EBV-related conditions.

68

69 Results and discussion

70

71 EBV genomes in blood and saliva from CAEBV patients

72 EBV blood genomes from CAEBV patients clustered with European/US sequences; longitudinal
73 samples, including those after PBSCT, clustered by patient (Supplementary figure 2). Within-host

CAEBV nucleotide diversity (π) was low and comparable to that of EBV from other blood samples (Table S1 and Supplementary figure 3-4). In contrast CAEBV salivary samples showed significantly higher EBV diversity compared to blood and tumour samples ($p < 0.001$), indicating the presence of multiple strains (Supplementary figure 5-7). Single nucleotide variants (SNVs) and small (<2kbp) deletions were present in all samples, largely located in latent genes as well as BPLF1 and BLLF1 [gp350] (Supplementary figures 8-16). Our results showed that EBV shed in saliva has the hallmarks of lytic replication and frequent mixed infections in line with previous studies (Kwok et al., 2015; Renzette et al., 2014).

Larger Deletions

We identified low frequency larger (>2kb) EBV deletion in patient 1, as well as PTLD (2/4) and HL (2/7) tumour-tissue at position 120470-158062 (Figure 1). This includes the BART miRNA clusters, as well as several lytic genes, including scaffold proteins (i.e. BDRF1, BVRF2), glycoproteins (i.e. BILF2, BXLF2), a tegument protein (BVRF1), and regulators of late gene transcription (BcRF1, BVLF1). Interestingly, patient 1 also had a nonsense mutation in BXLF2 (Supplementary Figure 17). A second larger deletion at positions 12118-15159, which is part of the major EBV repeat (IR1) was present in blood from CAEBV patients (4/4) and one patient with PID.

EBV variation overtime in CAEBV patients

Analysis of variation overtime revealed that the blood from two CAEBV patients (1 and 3) with EBV present predominantly in T cells, showed higher EBV genomic heterogeneity with increasing number of low frequency (<50%) variants and deletions than patients with IM (Figure 1D, Supplementary figures 18-19). In contrast, patient 2, whose EBV was only found in B cells, had fewer SNVs and deletions with a picture similar to that seen in the blood from patients with PTLD with evidence of clonality. In patient 2, larger deletions were stable overtime but were lost after rituximab (Figure 1D). In CAEBV patient 1, larger deletions persisted despite rituximab. Associated clinical

deterioration necessitated PBSCT (Table 1), following which both SNVs and deletions were absent from virus reactivating asymptotically. CAEBV patient 3, who also failed to respond to rituximab, lost most deletions, including the 12118-15159 IR1 deletion following PBSCT.

Discussion

EBV deletions were previously described only in CAEBV and malignancies patients of Asian origins (Murata et al., 2020; Okuno et al., 2019; Peng et al., 2019), however we show that these deletions occur independently of geographic origin. Data from mouse models suggest that loss of the BART miRNAs and late lytic genes within 120470-158062 deletion may drive a more lytic phenotype and faster cell growth, this predisposing to tumour formation (Lin et al., 2015; Ma et al., 2011; Murata et al., 2020). Although, the mechanism is not entirely clear, Murata and colleagues argue that the abortive EBV replication resulting from the absence of these regions prevents normal cell death associated with lytic replication (Murata et al., 2014, 2020).

The 12118-15159 deletion overlaps with the IR1 which includes BWRF1 and Wp promoters. There is no direct evidence yet that BWRF1 is biologically significant, however it is known that some components are essential for the transformation of cells by EBV. Our deletion is similar to one identified in strain L591, a Hodgkin's lymphoma cell line (breakpoint 125bp upstream of hairpin) (Palser et al., 2015). Persistence in longitudinally sampled blood of larger deletions has been associated with clonal expansion of the cells in which they are found (Okuno et al., 2019). Importantly we show that clinical response to therapy is associated with loss of deletions in virus recovered after treatment. Our findings of low-level potentially premalignant clones together with evidence of replicating virus in blood from patients with CAEBV fits with the hypothesis that deletions occur only when a particular subset of the patient's blood cells are infected with EBV. Progenitor lymphoid cells have been suggested to be the target cell type (Murata et al., 2014).

122

In conclusion, we confirm that clones containing EBV genomes with specific large deletions are found in blood but not saliva from CAEBV patients. While rituximab reduced the burden of EBV deletions in the blood of B cell-associated CAEBV, it had no impact on the prevalence of EBV deletions in T/NK-associated CAEBV. The absence of these EBV-deletions from virus reactivating following PBSCT suggests the loss of the pre-malignant clone and raises the possibility that these large deletions could be useful biomarkers for monitoring the success of treatments for CAEBV.

Materials and Methods

EBV dataset

We analysed a total of 94 EBV genome samples from nine groups: saliva from a healthy asymptomatic EBV carrier (healthy-S), blood from persons with infectious mononucleosis (IM-B), saliva (CAEBV-S) and blood (CAEBV-B) from persons with CAEBV, blood from a patient with persistent EBV viraemia and diagnosis of primary immunodeficiency (LRBA deficiency) (PID-B), blood from asymptomatic patients with EBV following organ transplantation (SOT-B), patients with post-transplant lymphoproliferative disease (PTLD-B) and tumour (PTLD-T) from patients with PTLD, and tumours from patients with Hodgkin lymphoma (HL-T). The samples and patients sequenced, and accession numbers are shown in Supplementary Table1 (Table S1).

Ethics and sample collection

EBV was sequenced directly from residual diagnostic whole blood samples stored at Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) at -80°C and obtained by the UCL Infection DNA Bank for use in this study. All samples were supplied to the study in an anonymised form.

Approval for use of anonymized residual diagnostic specimens were obtained through the University College London/University College London Hospitals (UCL/UCLH) Pathogen Biobank National Research Ethics Service Committee London Fulham (Research Ethics Committee reference: 12/LO/1089).

Saliva samples for CAEBV patients in US were approved by the National Institute of Allergy and Infectious Diseases and all subjects provided consent.

DNA extraction, library construction, targeted enrichment, and sequencing

Total DNA was extracted from each sample using the EZ1 Virus kit and EZ1 XL extraction system (Qiagen) according to manufacturer's instructions. Virus loads were established by an in-house NHS diagnostic qPCR assay (GOSH).

SureSelectXT Target Enrichment: RNA baits design

A library of 120-mer RNA baits spanning the length of 124 partial and complete EBV genomes from GenBank were designed using an in-house PERL script. Baits specificity was verified by BLASTn searches against the Human Genomic plus Transcript database. The custom designed EBV baits were uploaded to SureDesign and synthesised by Agilent Technologies.

SureSelectXT Target Enrichment: Library preparation, hybridisation and enrichment

Total DNA from clinical samples was quantified using the Qubit dsDNA HS assay kit (Life Technologies, Q32854) and between 200-500 ng of DNA was sheared for 150 seconds, using a Covaris E220 focused ultra-sonication system (PIP 175, duty factor 5, cycles per burst 200). End-repair, non-templated addition of 3' poly A, adapter ligation, hybridisation, PCR (12 cycles pre-capture and 18 or 22 cycles post capture) and all post-reaction clean-up steps were performed according to the SureSelectXT Automated Target Enrichment for Illumina Paired-End Multiplexed Sequencing 200 ng protocol (version F.2) on the Bravo platform WorkStation B (Agilent Technologies). All recommended quality control steps were performed on the 2200 TapeStation (Agilent Technologies).

Virus assembly

First, reads were trimmed using TrimGalore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with a quality threshold of 20 and then aligned with BLASTN against a database of 124 EBV type 1 and 2 genomes in order to

extract EBV-specific reads. They were then *de novo* assembled using SPAdes (Bankevich et al., 2012) into contigs, which were filtered for those of greater length than 200 bp with Quast. The order and orientation of contigs were determined with BLASTN and a scaffold being generated using an in-house R script. The quality checked reads were re-mapped against this pseudogenome using BBMap (<https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/>) and further processed into BAM-files with Samtools (v 1.9) (Li et al., 2009) and Picard (<https://broadinstitute.github.io/picard/>). The consensus sequences were extracted with an in-house PERL script.

Reference-based mapping was also performed for SNVs and deletions detection. The reference used was NC_007605.1 and mapping was performed with Bbmap (<https://jgi.doe.gov/data-and-tools/bbtools/bb-tools-user-guide/bbmap-guide/>).

Alignment and phylogenetic analysis

Sequences were aligned with Mafft (v.7) (Katoh et al., 2002) using default parameters. Multiple alignment was then checked manually with Aliview (Larsson, 2014). Distances and clustering were performed with custom R scripts, specifically using the `dist.dna` function in the “ape” package (Paradis & Schliep, 2019) and `cmdscale`, which implements classical multidimensional scaling (MDS).

Diversity calculation and haplotype reconstruction

Diversity calculations have been described elsewhere (Cudini et al., 2019) and code is available here <https://github.com/ucl-pathgenomics/NucleotideDiversity>. For haplotype reconstruction, we used HaROLD, which uses co-varying variant frequencies in a probabilistic framework. Validation and applications are described here (Cudini et al., 2019; Pang et al., 2020) and the program can be found here <https://github.com/ucl-pathgenomics/HaROLD>.

Minority variant analysis

After trimming with TrimGalore, fastq files were mapped to Genbank reference NC_007605.1 using BBmap. Duplicates were removed with Picard and bam files sorted with Samtools. Consensus files

were extracted with mpileup (included in Samtools) and QUASR (<https://github.com/simonjwatson/QUASR>). To focus our analysis only on minority variants (to capture within-host variation and not strain differences with the reference), we took the consensus file and mapped each sample to its own sequence. SNVs were then called with callvariants.sh in the BBmap suite if the frequency was $\geq 2\%$, read count ≥ 8 , strand ratio of 20% and callvariants.sh quality score > 0.8 . SNVs in repetitive regions were excluded according to NC_007605.1 positions. Genes annotation and plots were done using custom R scripts.

Deletions detection

After trimming with TrimGalore, fastq files were mapped to Genbank reference NC_007605.1 using BBmap allowing for reads to be split across the genome with default parameters. Duplicates were removed with Picard and bam files sorted with Samtools. Deletions were called with callvariants.sh in the BBmap suite with at least 5 reads supporting the split. Gene annotations and plots were done using custom R scripts.

Acknowledgements/Funding:

We thank Prof. Richard Goldstein (Division of Infection & Immunity, UCL) and Dr Daniel P. Depledge (NYU Department of Medicine) for insightful comments and discussion. We acknowledge the support of the MRC/NIHR funded Pathogen Genomics Unit.

CV was supported by the Wellcome Trust Collaborative Award [204870/Z/16/Z]; SM by a WT Henry Wellcome fellowship [206478/Z/17/Z]. PJF was supported by MRC grant MR/S022597/1 and by NIHR Imperial BRC. JB is supported by the NIHR UCL/UCLH BRC. This work was supported by the intramural research program of the National Institute of Allergy and Infectious Diseases.

Disclosure of conflicts of interest:

The authors declare no conflict of interest.

224

225 Figure Legends

226 **Figure 1A: Viraemia and treatment in GOSH CAEBV patient.** Patient 1 and 3 received PBST (in red)
227 and all patients received 4 to 5 doses of rituximab (blue lines). Samples sequenced are indicated in
228 grey filled dots.

229 **Figure 1B: Summary of deletions (≥ 30 bp).** Samples for healthy (healthy-S), infectious
230 mononucleosis (IM-B), CAEBV (CAEBV-S, CAEBV-B), primary immunodeficiency (PID) as well as EBV-
231 positive solid organ transplant (SOT-B), PTLD (PTLD-B and PTLD-T) and HL (HL-T). Each line
232 represents an EBV genome from a single patient (if multiple samples from one patient were
233 available, only the one with the highest read depth was included here).

234 **Figure 1C: Representation of the IR1 deletion in CAEBV.** Representative portion of the alignment
235 file for a blood CAEBV sample to demonstrate IR1 deletion (represented by red reads and black
236 lines) compared to an IM blood sample where the deletion is not present (reads in grey).

237 **Figure 1D: Analysis of longitudinal samples in CAEBV patients.** Genes affected by larger deletions ($\geq$
238 2k) are shown in the heatmap; overtime all larger deletions are lost. Non-synonymous low frequency
239 variants (<50%) are shown in the bubble plot.

240

241 Data availability:

242 Sequence reads for CAEBV and PID patients have been deposited in the European Nucleotide
243 Archive (ENA) under BioProject ID PRJEB41945. All accession numbers for the rest of the dataset are
244 available in Table S1.

245

246 Reference:

247 Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., Lesin, V. M.,
248 Nikolenko, S. I., Pham, S., Prjibelski, A. D., Pyshkin, A. V., Sirotkin, A. V., Vyahhi, N., Tesler, G.,
249 Alekseyev, M. A., & Pevzner, P. A. (2012). SPAdes: A New Genome Assembly Algorithm and

250 Its Applications to Single-Cell Sequencing. *Journal of Computational Biology*, 19(5), 455–477.
251 <https://doi.org/10.1089/cmb.2012.0021>

252 Cohen, J. I., Jaffe, E. S., Dale, J. K., Pittaluga, S., Heslop, H. E., Rooney, C. M., Gottschalk, S., Bollard, C.
253 M., Rao, V. K., Marques, A., Burbelo, P. D., Turk, S.-P., Fulton, R., Wayne, A. S., Little, R. F.,
254 Cairo, M. S., El-Mallawany, N. K., Fowler, D., Sportes, C., ... Straus, S. E. (2011).
255 Characterization and treatment of chronic active Epstein-Barr virus disease: A 28-year
256 experience in the United States. *Blood*, 117(22), 5835–5849. [https://doi.org/10.1182/blood-](https://doi.org/10.1182/blood-2010-11-316745)
257 2010-11-316745

258 Cudini, J., Roy, S., Houldcroft, C. J., Bryant, J. M., Depledge, D. P., Tutil, H., Veys, P., Williams, R.,
259 Worth, A. J. J., Tamuri, A. U., Goldstein, R. A., & Breuer, J. (2019). Human cytomegalovirus
260 haplotype reconstruction reveals high diversity due to superinfection and evidence of
261 within-host recombination. *Proceedings of the National Academy of Sciences*, 116(12),
262 5693–5698. <https://doi.org/10.1073/pnas.1818130116>

263 Katoh, K., Misawa, K., Kuma, K., & Miyata, T. (2002). MAFFT: A novel method for rapid multiple
264 sequence alignment based on fast Fourier transform. *Nucleic Acids Research*, 30(14), 3059–
265 3066. <https://doi.org/10.1093/nar/gkf436>

266 Kimura, H. (2006). Pathogenesis of chronic active Epstein-Barr virus infection: Is this an infectious
267 disease, lymphoproliferative disorder, or immunodeficiency? *Reviews in Medical Virology*,
268 16(4), 251–261. <https://doi.org/10.1002/rmv.505>

269 Kimura, H., & Cohen, J. I. (2017). Chronic Active Epstein–Barr Virus Disease. *Frontiers in Immunology*,
270 8. <https://doi.org/10.3389/fimmu.2017.01867>

271 Kwok, H., Chan, K. W., Chan, K. H., & Chiang, A. K. S. (2015). Distribution, Persistence and
272 Interchange of Epstein-Barr Virus Strains among PBMC, Plasma and Saliva of Primary
273 Infection Subjects. *PLOS ONE*, 10(3), e0120710.
274 <https://doi.org/10.1371/journal.pone.0120710>

275 Larsson, A. (2014). AliView: A fast and lightweight alignment viewer and editor for large datasets.
276 *Bioinformatics*, 30(22), 3276–3278. <https://doi.org/10.1093/bioinformatics/btu531>

277 Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R.,
278 & Subgroup, 1000 Genome Project Data Processing. (2009). The Sequence Alignment/Map
279 format and SAMtools. *Bioinformatics*, 25(16), 2078–2079.
280 <https://doi.org/10.1093/bioinformatics/btp352>

281 Lin, X., Tsai, M.-H., Shumilov, A., Poirey, R., Bannert, H., Middeldorp, J. M., Feederle, R., & Delecluse,
282 H.-J. (2015). The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates
283 Multiple Functions in Primary B Cells. *PLoS Pathogens*, 11(12).
284 <https://doi.org/10.1371/journal.ppat.1005344>

285 Longnecker, R. M., Kieff, E., & Cohen, J. I. (2013). *Epstein-barr virus*. Wolters Kluwer Health Adis
286 (ESP). <https://www.scholars.northwestern.edu/en/publications/epstein-barr-virus>

287 Ma, S.-D., Hegde, S., Young, K. H., Sullivan, R., Rajesh, D., Zhou, Y., Jankowska-Gan, E., Burlingham,
288 W. J., Sun, X., Gulley, M. L., Tang, W., Gumperz, J. E., & Kenney, S. C. (2011). A New Model of
289 Epstein-Barr Virus Infection Reveals an Important Role for Early Lytic Viral Protein Expression
290 in the Development of Lymphomas. *Journal of Virology*, 85(1), 165–177.
291 <https://doi.org/10.1128/JVI.01512-10>

292 Murata, T., Okuno, Y., Sato, Y., Watanabe, T., & Kimura, H. (2020). Oncogenesis of CAEBV revealed:
293 Intragenic deletions in the viral genome and leaky expression of lytic genes. *Reviews in*
294 *Medical Virology*, 30(2), e2095. <https://doi.org/10.1002/rmv.2095>

295 Murata, T., Sato, Y., & Kimura, H. (2014). Modes of infection and oncogenesis by the Epstein–Barr
296 virus. *Reviews in Medical Virology*, 24(4), 242–253. <https://doi.org/10.1002/rmv.1786>

297 Ohshima, K., Suzumiya, J., Ohga, S., Ohgami, A., & Kikuchi, M. (1997). Integrated Epstein-Barr virus
298 (EBV) and chromosomal abnormality in chronic active EBV infection. *International Journal of*
299 *Cancer*, 71(6), 943–947. [https://doi.org/10.1002/\(SICI\)1097-0215\(19970611\)71:6<943::AID-](https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<943::AID-IJC5>3.0.CO;2-Y)
300 [IJC5>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<943::AID-IJC5>3.0.CO;2-Y)

301 Okuno, Y., Murata, T., Sato, Y., Muramatsu, H., Ito, Y., Watanabe, T., Okuno, T., Murakami, N.,
302 Yoshida, K., Sawada, A., Inoue, M., Kawa, K., Seto, M., Ohshima, K., Shiraishi, Y., Chiba, K.,
303 Tanaka, H., Miyano, S., Narita, Y., ... Kimura, H. (2019). Defective Epstein–Barr virus in
304 chronic active infection and haematological malignancy. *Nature Microbiology*, 4(3), 404.
305 <https://doi.org/10.1038/s41564-018-0334-0>

306 Palser, A. L., Grayson, N. E., White, R. E., Corton, C., Correia, S., Abdullah, M. M. B., Watson, S. J.,
307 Cotten, M., Arrand, J. R., Murray, P. G., Allday, M. J., Rickinson, A. B., Young, L. S., Farrell, P.
308 J., & Kellam, P. (2015). Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types
309 and Normal Infection. *Journal of Virology*, 89(10), 5222–5237.
310 <https://doi.org/10.1128/JVI.03614-14>

311 Pang, J., Venturini, C., Tamuri, A. U., Roy, S., Breuer, J., & Goldstein, R. A. (2020). Haplotype
312 assignment of longitudinal viral deep-sequencing data using co-variation of variant
313 frequencies. *BioRxiv*, 444877. <https://doi.org/10.1101/444877>

314 Paradis, E., & Schliep, K. (2019). ape 5.0: An environment for modern phylogenetics and evolutionary
315 analyses in R. *Bioinformatics*, 35(3), 526–528.
316 <https://doi.org/10.1093/bioinformatics/bty633>

317 Peng, R.-J., Han, B.-W., Cai, Q.-Q., Zuo, X.-Y., Xia, T., Chen, J.-R., Feng, L.-N., Lim, J. Q., Chen, S.-W.,
318 Zeng, M.-S., Guo, Y.-M., Li, B., Xia, X.-J., Xia, Y., Laurensia, Y., Chia, B. K. H., Huang, H.-Q.,
319 Young, K. H., Lim, S. T., ... Bei, J.-X. (2019). Genomic and transcriptomic landscapes of
320 Epstein-Barr virus in extranodal natural killer T-cell lymphoma. *Leukemia*, 33(6), 1451–1462.
321 <https://doi.org/10.1038/s41375-018-0324-5>

322 Quintanilla-Martinez, L., Kumar, S., Fend, F., Reyes, E., Teruya-Feldstein, J., Kingma, D. W., Sorbara,
323 L., Raffeld, M., Straus, S. E., & Jaffe, E. S. (2000). Fulminant EBV+ T-cell lymphoproliferative
324 disorder following acute/chronic EBV infection: A distinct clinicopathologic syndrome. *Blood*,
325 96(2), 443–451. <https://doi.org/10.1182/blood.V96.2.443>

326 Renzette, N., Somasundaran, M., Brewster, F., Coderre, J., Weiss, E. R., McManus, M., Greenough, T.,
327 Tabak, B., Garber, M., Kowalik, T. F., & Luzuriaga, K. (2014). EBV Latent Membrane Protein 1
328 genetic variability in peripheral blood B cells and oropharyngeal fluids. *Journal of Virology*,
329 JVI.03378-13. <https://doi.org/10.1128/JVI.03378-13>
330
331

A)

B)

C)

D)

Figure 1

Pat	Sex	Description	Treatment	Transplant	Reactivation	N samples
P1	M	<ul style="list-style-type: none"> EBV driven HLH primary and secondary immunodeficiency excluded 	<ul style="list-style-type: none"> HLH 94 protocol 5 doses of Rituximab (pre-transplant) 	Alemtuzumab/Fludarabine/Melphalan conditioned matched unrelated donor (MUD) peripheral blood stem cell transplant (PBSCT)	4 months post HST had reactivation of EBV without signs of PTLD and resolved without therapy	7
P2	F	<ul style="list-style-type: none"> EBV driven HLH primary and secondary immunodeficiency excluded 	<ul style="list-style-type: none"> HLH 94 protocol 4 doses of Rituximab 	The patient did not proceed to BMT as she responded well to HLH treatment and had no evidence of ongoing HLH activity despite ongoing EBV viraemia	Remained EBV PCR positive for 3.5 years without symptoms. As of November 2018, EBV PCR is negative.	3
P3	F	<ul style="list-style-type: none"> EBV driven HLH, spontaneously resolved without treatment. Over the following 6 months she had two further EBV-related HLH relapses treated with steroids. Although her HLH associated symptoms rapidly responded, her EBV viraemia continued to rise. primary and secondary immunodeficiency excluded During the 3rd HLH relapse treatment course patient had multiple complications (renal failure requiring haemofiltration, atrial fibrillation requiring DC cardioversion, adenovirus and CMV viremias, invasive candida parapsilosis enteritis, facial palsy) 	<ul style="list-style-type: none"> 4 doses of rituximab with successfully depleted B cells but not reduced EBV viral load (pre-transplant) After 3rd HLH relapse was commenced on etoposide as per HLH 94 protocol with resolution of clinical symptoms and reduction in EBV viral load. 1 dose of rituximab after transplant 	Alemtuzumab/Fludarabine/Treosulfan conditioned matched sibling donor (MSD) peripheral blood stem cell transplant	EBV reactivation that resolved after 1 dose of Rituximab.	5

Table 1: Patients descriptions and clinical details